This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
| bigram | frequency |
|---|---|
| respiratory syndrome | 3673 |
| middle east | 3605 |
| east respiratory | 3197 |
| syndrome coronavirus | 2714 |
| saudi arabia | 1078 |
| cov infection | 1042 |
| acute respiratory | 687 |
| dromedary camels | 652 |
| coronavirus infection | 529 |
| severe acute | 523 |
| south korea | 393 |
| respiratory tract | 375 |
| mers coronavirus | 312 |
| novel coronavirus | 311 |
| spike protein | 259 |
| risk factors | 253 |
| health care | 229 |
| human coronavirus | 228 |
| public health | 225 |
| infection control | 210 |
| viral rna | 201 |
| cov cases | 197 |
| human transmission | 191 |
| world health | 189 |
| infectious diseases | 188 |
| health organization | 181 |
| neutralizing antibodies | 178 |
| confirmed cases | 178 |
| healthcare workers | 170 |
| human security | 166 |
| united states | 152 |
| arabian peninsula | 149 |
| cov infections | 148 |
| coronavirus infections | 148 |
| tg mice | 148 |
| lower respiratory | 147 |
| mers patients | 142 |
| cord uid | 141 |
| doc id | 141 |
| incubation period | 140 |
| dipeptidyl peptidase | 136 |
| confirmed mers | 133 |
| animal models | 133 |
| mouse model | 132 |
| hemorrhagic fever | 129 |
| upper respiratory | 127 |
| binding domain | 122 |
| rhesus macaques | 122 |
| immune response | 122 |
| cov outbreak | 121 |
| hong kong | 121 |
| clinical features | 119 |
| respiratory disease | 117 |
| mers cases | 114 |
| infectious virus | 112 |
| novel human | 110 |
| east asia | 109 |
| respiratory illness | 109 |
| dromedary camel | 107 |
| fatality rate | 107 |
| sars coronavirus | 107 |
| clinical characteristics | 107 |
| hospital outbreak | 105 |
| symptom onset | 105 |
| intensive care | 104 |
| respiratory distress | 103 |
| control measures | 103 |
| closely related | 102 |
| united arab | 102 |
| arab emirates | 101 |
| food safety | 101 |
| cov transmission | 101 |
| immune responses | 100 |
| infectious disease | 98 |
| infected patients | 98 |
| type i | 98 |
| influenza virus | 97 |
| critically ill | 97 |
| infection prevention | 97 |
| epithelial cells | 96 |
| respiratory failure | 95 |
| viral load | 95 |
| severe respiratory | 95 |
| viral shedding | 94 |
| bronze age | 94 |
| coronavirus disease | 93 |
| cov patients | 93 |
| cov spike | 93 |
| distress syndrome | 91 |
| arabia middle | 91 |
| cov rna | 90 |
| systematic review | 90 |
| ill patients | 89 |
| cov antibodies | 88 |
| respiratory symptoms | 87 |
| human infection | 87 |
| mers outbreak | 86 |
| virus infection | 86 |
| emerging infectious | 85 |
| severe disease | 84 |
| chain reaction | 83 |
| borne encephalitis | 83 |
| east asian | 82 |
| avian influenza | 82 |
| monoclonal antibodies | 80 |
| polymerase chain | 80 |
| disease control | 79 |
| case fatality | 79 |
| mortality rate | 78 |
| amino acid | 78 |
| monoclonal antibody | 77 |
| care workers | 76 |
| west nile | 76 |
| mers cov | 76 |
| mechanical ventilation | 75 |
| convalescent plasma | 75 |
| ebola virus | 74 |
| human cases | 74 |
| secondary cases | 74 |
| innate immune | 74 |
| respiratory infections | 73 |
| fever virus | 73 |
| descriptive study | 73 |
| serum samples | 73 |
| clinical trials | 73 |
| phylogenetic analysis | 73 |
| transgenic mice | 72 |
| healthcare settings | 70 |
| family cluster | 70 |
| emergency room | 69 |
| natural foci | 69 |
| congo hemorrhagic | 69 |
| household contacts | 68 |
| close contact | 67 |
| viral replication | 67 |
| coronavirus spike | 67 |
| case definition | 66 |
| time reverse | 66 |
| within days | 65 |
| nosocomial transmission | 65 |
| neutralizing antibody | 65 |
| vaccine candidates | 65 |
| care facilities | 65 |
| encephalitis virus | 65 |
| coronavirus hku | 64 |
| cases reported | 64 |
| weight loss | 62 |
| coronavirus replication | 61 |
| influenza viruses | 60 |
| serological study | 60 |
| imported case | 60 |
| human coronaviruses | 59 |
| coronavirus middle | 59 |
| cell lines | 59 |
| mycophenolic acid | 59 |
| healthcare worker | 58 |
| middle eastern | 58 |
| cell culture | 58 |
| care unit | 58 |
| common marmoset | 58 |
| direct contact | 58 |
| viral infection | 58 |
| animal model | 58 |
| hospitalized patients | 58 |
| specific antibodies | 57 |
| respiratory viruses | 57 |
| infected camels | 57 |
| viral loads | 57 |
| highly pathogenic | 57 |
| cov replication | 57 |
| two cases | 56 |
| epi isl | 55 |
| healthcare facilities | 55 |
| human mers | 55 |
| nucleocapsid protein | 55 |
| suspected cases | 54 |
| index case | 54 |
| nile virus | 54 |
| cov case | 54 |
| illness onset | 54 |
| clinical course | 54 |
| northern eurasia | 53 |
| respiratory infection | 53 |
| common marmosets | 53 |
| lopinavir ritonavir | 53 |
| renal failure | 53 |
| severe pneumonia | 53 |
| previous studies | 53 |
| clinical signs | 53 |
| severe mers | 52 |
| patients infected | 52 |
| previously described | 52 |
| cohort study | 52 |
| statistically significant | 51 |
| food poisoning | 51 |
| bat coronavirus | 51 |
| cov infected | 50 |
| may also | 50 |
| human monoclonal | 50 |
| nasal swabs | 50 |
| functional receptor | 50 |
| southeast asia | 50 |
| high risk | 50 |
| study middle | 49 |
| spike glycoprotein | 49 |
| far east | 49 |
| data collection | 49 |
| outbreak investigation | 48 |
| receptor binding | 47 |
| reverse transcription | 47 |
| bat coronaviruses | 47 |
| wild birds | 47 |
| human dpp | 46 |
| experimental infection | 46 |
| laboratory testing | 46 |
| emerging human | 45 |
| tract infection | 45 |
| reported cases | 45 |
| human infections | 45 |
| abu dhabi | 45 |
| korean outbreak | 44 |
| viral infections | 44 |
| structural proteins | 44 |
| clinical symptoms | 44 |
| infection rate | 44 |
| among healthcare | 43 |
| vero cells | 43 |
| large number | 43 |
| significantly higher | 43 |
| transmission dynamics | 43 |
| host cell | 43 |
| life insurance | 43 |
| virus strains | 43 |
| case patients | 43 |
| cell entry | 43 |
| clinical presentation | 42 |
| cov vaccine | 42 |
| contact tracing | 42 |
| serum antibodies | 42 |
| based vaccine | 42 |
| nosocomial outbreaks | 42 |
| human respiratory | 42 |
| risk factor | 42 |
| associated coronavirus | 42 |
| retrospective cohort | 42 |
| strains isolated | 41 |
| human betacoronavirus | 41 |
| coronavirus mers | 41 |
| neutralizing monoclonal | 41 |
| experimentally infected | 41 |
| mycophenolate mofetil | 41 |
| predictive factors | 41 |
| high mortality | 41 |
| control study | 41 |
| coronavirus associated | 40 |
| infection among | 40 |
| hospital outbreaks | 40 |
| personal protective | 40 |
| like protease | 40 |
| rna viruses | 40 |
| close contacts | 40 |
| corona virus | 40 |
| recovery delay | 40 |
| fruit bat | 40 |
| global health | 40 |
| complete genome | 40 |
| high prevalence | 39 |
| fi rst | 39 |
| present study | 39 |
| amino acids | 39 |
| first case | 39 |
| tested positive | 39 |
| genome sequence | 39 |
| improves outcome | 39 |
| retrospective study | 39 |
| suspected mers | 39 |
| interferon alfa | 39 |
| antibody response | 39 |
| dialysis patients | 38 |
| observational study | 38 |
| healthcare personnel | 38 |
| vertebrate hosts | 37 |
| imported cases | 37 |
| human disease | 37 |
| human population | 37 |
| south korean | 37 |
| one study | 37 |
| virus disease | 37 |
| coronavirus oc | 37 |
| protective equipment | 37 |
| disease severity | 37 |
| respiratory samples | 37 |
| laboratory findings | 37 |
| bubonic plague | 37 |
| neutralising antibodies | 37 |
| median age | 37 |
| associated outbreak | 36 |
| zoonotic transmission | 36 |
| mva mers | 36 |
| infected animals | 36 |
| near east | 36 |
| japanese encephalitis | 36 |
| older age | 36 |
| converting enzyme | 36 |
| immune system | 36 |
| arthropod vectors | 36 |
| tertiary care | 36 |
| comparative serological | 36 |
| confirmed case | 36 |
| performed using | 36 |
| disease outbreak | 36 |
| sporadic cases | 35 |
| united nations | 35 |
| clinical aspects | 35 |
| icu admission | 35 |
| therapeutic options | 35 |
| jamaican fruit | 35 |
| fruit bats | 35 |
| vaccinia virus | 35 |
| even though | 35 |
| family members | 35 |
| open reading | 35 |
| infected mice | 35 |
| asymptomatic cases | 35 |
| united kingdom | 35 |
| increased risk | 35 |
| north america | 34 |
| cov virus | 34 |
| cellular immune | 34 |
| clinical outcomes | 34 |
| chikungunya virus | 34 |
| vaccine development | 34 |
| human neutralizing | 34 |
| laboratory confirmation | 34 |
| cov antigen | 34 |
| phylogenetic tree | 34 |
| chadox mers | 34 |
| clinical trial | 34 |
| first imported | 34 |
| days post | 33 |
| lung disease | 33 |
| gastrointestinal symptoms | 33 |
| travel history | 33 |
| reported mers | 33 |
| mers coronaviruses | 33 |
| insurance companies | 33 |
| gene expression | 33 |
| fatal cases | 33 |
| coronavirus transmission | 33 |
| western siberia | 33 |
| study design | 33 |
| membrane fusion | 33 |
| data gaps | 33 |
| coronavirus neutralising | 33 |
| nonhuman primates | 33 |
| virus replication | 33 |
| healthcare setting | 33 |
| protective efficacy | 32 |
| authors declare | 32 |
| neutralising serum | 32 |
| clinical manifestations | 32 |
| infect dis | 32 |
| tissue culture | 32 |
| risk assessment | 32 |
| case report | 32 |
| rift valley | 32 |
| person transmission | 32 |
| coronavirus receptor | 32 |
| slaughterhouse workers | 32 |
| type ii | 32 |
| astrakhan region | 32 |
| prediction model | 31 |
| mortality rates | 31 |
| interstitial pneumonia | 31 |
| high levels | 31 |
| genetic diversity | 31 |
| eastern respiratory | 31 |
| mouse models | 31 |
| coronavirus outbreak | 31 |
| patients received | 31 |
| coronavirus pneumonia | 31 |
| acute renal | 31 |
| pcr testing | 31 |
| respiratory coronavirus | 31 |
| camels middle | 31 |
| insurance market | 31 |
| total number | 31 |
| severe cases | 31 |
| transcription polymerase | 31 |
| ticks collected | 31 |
| domestic animals | 31 |
| syndrome outbreak | 31 |
| cov strains | 31 |
| bronchial epithelial | 30 |
| dna vaccine | 30 |
| another study | 30 |
| animal species | 30 |
| sars outbreak | 30 |
| care hospital | 30 |
| symptomatic cases | 30 |
| antibody responses | 30 |
| severe middle | 30 |
| case reports | 30 |
| tract infections | 30 |
| logistic regression | 30 |
| clinical management | 30 |
| cell line | 30 |
| medical center | 30 |
| international catalogue | 30 |
| diabetes mellitus | 29 |
| pneumonia development | 29 |
| inflammatory cells | 29 |
| clinical description | 29 |
| coronavirus vaccine | 29 |
| arabia mers | 29 |
| viral respiratory | 29 |
| single patient | 29 |
| organ failure | 29 |
| human dipeptidyl | 29 |
| alveolar damage | 29 |
| based vaccines | 29 |
| fatal case | 29 |
| spreading events | 29 |
| affected countries | 29 |
| transgenic mouse | 29 |
| modified vaccinia | 29 |
| respiratory specimens | 29 |
| new coronavirus | 29 |
| cov rbd | 29 |
| infectious bronchitis | 29 |
| virus infections | 28 |
| tract samples | 28 |
| old tg | 28 |
| accessory proteins | 28 |
| primorsky krai | 28 |
| genetic characterization | 28 |
| antiviral activity | 28 |
| control practices | 28 |
| natural reservoir | 28 |
| protective immunity | 28 |
| medical conditions | 28 |
| genomic characterization | 28 |
| saudi ministry | 28 |
| korea middle | 28 |
| bovine coronavirus | 28 |
| tcid ml | 28 |
| health authorities | 28 |
| described previously | 28 |
| animal reservoir | 28 |
| high viral | 28 |
| emergency department | 28 |
| mers infection | 28 |
| supportive care | 28 |
| human middle | 28 |
| lung injury | 28 |
| camel contact | 28 |
| day post | 28 |
| respiratory diseases | 28 |
| dis doi | 27 |
| patients admitted | 27 |
| cov epidemic | 27 |
| competing interests | 27 |
| biosafety level | 27 |
| better understand | 27 |
| interferon therapy | 27 |
| mildly symptomatic | 27 |
| antiviral agents | 27 |
| coronavirus antibodies | 27 |
| generating procedures | 27 |
| geographic distribution | 27 |
| virological analysis | 27 |
| coronavirus emc | 27 |
| outbreak news | 27 |
| throat swabs | 27 |
| phase i | 27 |
| first reported | 27 |
| years old | 27 |
| genome sequences | 27 |
| nasal swab | 27 |
| camel mers | 27 |
| food security | 27 |
| contact investigation | 27 |
| acquired pneumonia | 27 |
| related viruses | 27 |
| mers case | 27 |
| coronavirus neutralizing | 27 |
| potential risk | 27 |
| available data | 27 |
| hospital transmission | 27 |
| germ warfare | 26 |
| asymptomatic infection | 26 |
| days prior | 26 |
| viral titers | 26 |
| camel herd | 26 |
| cov causes | 26 |
| virus isolation | 26 |
| first isolated | 26 |
| volga delta | 26 |
| postexposure efficacy | 26 |
| high level | 26 |
| case series | 26 |
| virus transmission | 26 |
| current situation | 26 |
| clinical data | 26 |
| hajj pilgrims | 26 |
| cov vaccines | 26 |
| asian countries | 26 |
| acute kidney | 26 |
| high fatality | 26 |
| mers outbreaks | 26 |
| virus ankara | 26 |
| mean age | 26 |
| new zealand | 25 |
| mg ml | 25 |
| nasal discharge | 25 |
| lung tissue | 25 |
| nervous system | 25 |
| animal health | 25 |
| care settings | 25 |
| study showed | 25 |
| two groups | 25 |
| livestock species | 25 |
| renal replacement | 25 |
| primate model | 25 |
| host species | 25 |
| international committee | 25 |
| emerging pathogens | 25 |
| emerging coronaviruses | 25 |
| strain leiv | 25 |
| lung pathology | 25 |
| cov challenge | 25 |
| valley fever | 25 |
| cell responses | 25 |
| hand hygiene | 25 |
| fi gure | 25 |
| factors associated | 25 |
| i interferon | 25 |
| among patients | 25 |
| cause severe | 25 |
| camel milk | 25 |
| foodborne disease | 25 |
| genome sequencing | 25 |
| multiorgan failure | 24 |
| investigation team | 24 |
| virus shedding | 24 |
| confi rmed | 24 |
| food handlers | 24 |
| recent study | 24 |
| virus excretion | 24 |
| ii pneumocytes | 24 |
| including deaths | 24 |
| host cells | 24 |
| results suggest | 24 |
| replacement therapy | 24 |
| bat species | 24 |
| healthcare facility | 24 |
| new virus | 24 |
| time pcr | 24 |
| primary cases | 24 |
| antiviral therapy | 24 |
| caspian sea | 24 |
| respiratory syncytial | 24 |
| borne viruses | 24 |
| stranded rna | 24 |
| viral entry | 24 |
| plaque reduction | 24 |
| haemorrhagic fever | 24 |
| center experience | 24 |
| early stage | 24 |
| combination therapy | 23 |
| inhibits mers | 23 |
| endothelial cells | 23 |
| clinical specimens | 23 |
| indirect contact | 23 |
| viral genome | 23 |
| canary islands | 23 |
| newly discovered | 23 |
| creative commons | 23 |
| polyprotein precursor | 23 |
| major livestock | 23 |
| control groups | 23 |
| reproduction number | 23 |
| viruses isolated | 23 |
| camel sera | 23 |
| general population | 23 |
| transmission within | 23 |
| medical care | 23 |
| cell cultures | 23 |
| reading frame | 23 |
| median time | 23 |
| central asia | 23 |
| viral antigen | 23 |
| virus isolated | 23 |
| kidney injury | 23 |
| primary middle | 23 |
| syncytial virus | 23 |
| much higher | 23 |
| epidemiological investigation | 23 |
| illness caused | 23 |
| chest pain | 22 |
| infected rhesus | 22 |
| epidemiological data | 22 |
| time series | 22 |
| family contacts | 22 |
| subunit vaccine | 22 |
| confidence interval | 22 |
| transmission among | 22 |
| bl mice | 22 |
| host factors | 22 |
| inflammatory cytokines | 22 |
| nonstructural proteins | 22 |
| virus neutralisation | 22 |
| rna virus | 22 |
| insectivorous bats | 22 |
| ce serocomplex | 22 |
| target cells | 22 |
| human airway | 22 |
| viral diagnosis | 22 |
| tested negative | 22 |
| severe illness | 22 |
| critical care | 22 |
| animal studies | 22 |
| syndrome middle | 22 |
| significant differences | 22 |
| important role | 22 |
| healthcare systems | 22 |
| spike gene | 22 |
| cov pathogenesis | 22 |
| vaccine candidate | 22 |
| ixodidae ticks | 22 |
| domestic livestock | 22 |
| coronavirus causes | 22 |
| diff erent | 22 |
| also known | 22 |
| discovered coronavirus | 22 |
| eastern mediterranean | 21 |
| tracheal aspirates | 21 |
| literature update | 21 |
| cov neutralizing | 21 |
| sea peoples | 21 |
| ribavirin improves | 21 |
| based study | 21 |
| genomic rna | 21 |
| first mers | 21 |
| mice showed | 21 |
| treatment options | 21 |
| small number | 21 |
| rna polymerase | 21 |
| social media | 21 |
| medical countermeasures | 21 |
| genbank accession | 21 |
| asymptomatic mers | 21 |
| membrane oxygenation | 21 |
| one patient | 21 |
| spectrum antiviral | 21 |
| associated outbreaks | 21 |
| protease inhibitors | 21 |
| potent neutralization | 21 |
| bronchitis virus | 21 |
| swab samples | 21 |
| identifi ed | 21 |
| molecular epidemiology | 21 |
| medical records | 21 |
| comparative analysis | 21 |
| several studies | 21 |
| nonhuman primate | 21 |
| pregnant women | 21 |
| also found | 21 |
| interferon beta | 21 |
| study group | 21 |
| mortality risk | 21 |
| vitro studies | 21 |
| tahyna virus | 21 |
| tg mouse | 21 |
| samples collected | 21 |
| hdpp transgenic | 21 |
| bronchoalveolar lavage | 21 |
| like viruses | 21 |
| coronavirus species | 21 |
| korea outbreak | 21 |
| renal disease | 21 |
| also reported | 21 |
| least one | 21 |
| fatality rates | 21 |
| investigation middle | 20 |
| asian tigers | 20 |
| human primates | 20 |
| affected region | 20 |
| bhanja virus | 20 |
| camel coronavirus | 20 |
| single dose | 20 |
| related patients | 20 |
| higher risk | 20 |
| virus entry | 20 |
| environmental conditions | 20 |
| high case | 20 |
| dpp receptor | 20 |
| causes lethal | 20 |
| coronavirus seroprevalence | 20 |
| operating room | 20 |
| two mers | 20 |
| cov outbreaks | 20 |
| novel middle | 20 |
| pegylated interferon | 20 |
| review board | 20 |
| times higher | 20 |
| although mers | 20 |
| envelope protein | 20 |
| negative pressure | 20 |
| mers patient | 20 |
| new york | 20 |
| reduces virus | 20 |
| african countries | 20 |
| virus taxonomy | 20 |
| vaccine reduces | 20 |
| etiological agent | 20 |
| electron microscopy | 20 |
| institutional review | 20 |
| mers vaccines | 20 |
| serologic testing | 20 |
| heart disease | 20 |
| three camel | 20 |
| sars patients | 20 |
| virus load | 20 |
| copyright holder | 20 |
| one health | 20 |
| crystal structure | 20 |
| infected patient | 20 |
| viral spike | 20 |
| pipistrellus bat | 20 |
| previously reported | 20 |
| median incubation | 19 |
| reverse transcriptase | 19 |
| interim guidance | 19 |
| central nervous | 19 |
| healthcare system | 19 |
| pcr assay | 19 |
| unrecognized asymptomatic | 19 |
| infections among | 19 |
| lymph nodes | 19 |
| diffuse alveolar | 19 |
| coronavirus using | 19 |
| two patients | 19 |
| time rt | 19 |
| southeastern asia | 19 |
| patient exposure | 19 |
| descriptive genomic | 19 |
| pediatric patients | 19 |
| different countries | 19 |
| nipah virus | 19 |
| rhesus macaque | 19 |
| extracorporeal membrane | 19 |
| underlying medical | 19 |
| dpp expression | 19 |
| survival rates | 19 |
| transient lower | 19 |
| attack rate | 19 |
| primary human | 19 |
| european countries | 19 |
| serological evidence | 19 |
| mice infected | 19 |
| cov among | 19 |
| coronavirus among | 19 |
| camels mers | 19 |
| ultrastructural findings | 19 |
| old man | 19 |
| respiratory secretions | 19 |
| sore throat | 19 |
| common pipistrelle | 19 |
| human beings | 19 |
| pcr assays | 19 |
| coronavirus illness | 19 |
| publicly available | 19 |
| pandemic influenza | 19 |
| cov shedding | 19 |
| genomic study | 19 |
| sandfly fever | 19 |
| avian coronaviruses | 19 |
| vaccinated group | 19 |
| among camels | 19 |
| human covs | 19 |
| horseshoe bats | 19 |
| betacoronavirus lineage | 19 |
| human antibodies | 18 |
| among humans | 18 |
| instillation group | 18 |
| syndrome corona | 18 |
| disease prevention | 18 |
| potential conflicts | 18 |
| index patient | 18 |
| developing countries | 18 |
| like virus | 18 |
| late bronze | 18 |
| treatment group | 18 |
| inoculated dromedary | 18 |
| respiratory pathogens | 18 |
| nasopharyngeal swabs | 18 |
| pandemic potential | 18 |
| among children | 18 |
| serocomplex viruses | 18 |
| urgently needed | 18 |
| see note | 18 |
| associated middle | 18 |
| first cases | 18 |
| relatively low | 18 |
| tract specimens | 18 |
| body temperature | 18 |
| full genome | 18 |
| dengue virus | 18 |
| antibody titers | 18 |
| spike proteins | 18 |
| whole genome | 18 |
| acute middle | 18 |
| infectious peritonitis | 18 |
| higher viral | 18 |
| host proteases | 18 |
| ct values | 18 |
| environmental contamination | 18 |
| prospective study | 18 |
| post inoculation | 18 |
| like particles | 18 |
| clinical studies | 18 |
| likely unrecognized | 18 |
| better understanding | 18 |
| studies showed | 18 |
| health response | 18 |
| sequence analysis | 18 |
| three years | 18 |
| comparative study | 18 |
| nairovirus genus | 18 |
| human rights | 18 |
| body weight | 18 |
| medical city | 18 |
| viral proteins | 18 |
| infections related | 18 |
| mild case | 18 |
| attack rates | 18 |
| abdominal pain | 18 |
| fully human | 18 |
| uukuniemi virus | 17 |
| dpp binding | 17 |
| terminal domain | 17 |
| cov antibody | 17 |
| two different | 17 |
| fusion protein | 17 |
| pathological changes | 17 |
| previous reports | 17 |
| russian plain | 17 |
| early stages | 17 |
| protein induces | 17 |
| room temperature | 17 |
| rapid generation | 17 |
| european part | 17 |
| close relative | 17 |
| significantly lower | 17 |
| transmission routes | 17 |
| chikungunya fever | 17 |
| serological testing | 17 |
| cov sequences | 17 |
| mouse dpp | 17 |
| south africa | 17 |
| cov activity | 17 |
| pathogenic avian | 17 |
| mg kg | 17 |
| among different | 17 |
| cov genome | 17 |
| subunit vaccines | 17 |
| ex vivo | 17 |
| cov seropositivity | 17 |
| cases may | 17 |
| inhibit mers | 17 |
| among dromedary | 17 |
| study mers | 17 |
| secondary transmission | 17 |
| genus betacoronavirus | 17 |
| index cases | 17 |
| limited number | 17 |
| linked immunosorbent | 17 |
| studies reported | 17 |
| egyptian fruit | 17 |
| intestinal tract | 17 |
| diagnostic tests | 17 |
| treat middle | 17 |
| risk prediction | 17 |
| hittite empire | 17 |
| pandemic risk | 17 |
| viral diseases | 17 |
| exposed patients | 17 |
| lethal pneumonia | 17 |
| nucleic acid | 17 |
| odds ratio | 17 |
| surveillance systems | 17 |
| genome analysis | 17 |
| study period | 17 |
| bat origin | 17 |
| nosocomial outbreak | 17 |
| disease surveillance | 17 |
| many countries | 17 |
| humanized mouse | 17 |
| eastern countries | 17 |
| feline infectious | 17 |
| infected individuals | 17 |
| first detected | 17 |
| uukuniemi group | 17 |
| length genome | 17 |
| infected dromedary | 17 |
| challenged mice | 17 |
| cov viral | 17 |
| epidemic potential | 17 |
| therapeutic agents | 17 |
| saudi arabian | 17 |
| large outbreak | 17 |
| cov strain | 17 |
| emc strain | 17 |
| viral titer | 17 |
| cases among | 17 |
| central europe | 17 |
| iu ml | 17 |
| swab specimens | 17 |
| study clinical | 17 |
| control group | 16 |
| remains unclear | 16 |
| human isolates | 16 |
| hospital patients | 16 |
| clinical presentations | 16 |
| airborne transmission | 16 |
| large outbreaks | 16 |
| symptomatic patients | 16 |
| heptad repeat | 16 |
| lactate dehydrogenase | 16 |
| sequence identity | 16 |
| made available | 16 |
| higher mers | 16 |
| intranasal inoculation | 16 |
| preventive measures | 16 |
| five patients | 16 |
| control guidelines | 16 |
| pcr tests | 16 |
| syncytial cells | 16 |
| lung tissues | 16 |
| included studies | 16 |
| bunyaviridae family | 16 |
| patients may | 16 |
| negative control | 16 |
| omsk hemorrhagic | 16 |
| plasma therapy | 16 |
| antiviral response | 16 |
| specific antiviral | 16 |
| measles virus | 16 |
| low levels | 16 |
| neutralization test | 16 |
| mass gatherings | 16 |
| molecular basis | 16 |
| fatal mers | 16 |
| supplementary material | 16 |
| samsung medical | 16 |
| first confirmed | 16 |
| first identified | 16 |
| positive results | 16 |
| neighboring countries | 16 |
| live virus | 16 |
| aerosol group | 16 |
| sample size | 16 |
| coronavirus study | 16 |
| pipistrelle bat | 16 |
| two strains | 16 |
| accession number | 16 |
| cov emc | 16 |
| broad spectrum | 16 |
| treatment strategies | 16 |
| air travel | 16 |
| camel population | 16 |
| outbreak study | 16 |
| zoonotic origin | 16 |
| randomized controlled | 16 |
| million people | 16 |
| alveolar macrophages | 16 |
| neutralisation assays | 16 |
| respiratory virus | 16 |
| vitro activity | 16 |
| outbreak outside | 16 |
| supplementary table | 16 |
| dhabi emirate | 16 |
| lethal disease | 16 |
| bactrian camels | 16 |
| mouse hepatitis | 16 |
| septic shock | 16 |
| camel herds | 16 |
| statistical analyses | 16 |
| phylogenetic analyses | 16 |
| dendritic cells | 16 |
| market workers | 16 |
| antiviral treatment | 16 |
| results showed | 16 |
| related deaths | 16 |
| infectious agents | 16 |
| eastern europe | 16 |
| nucleotide sequence | 16 |
| relatively high | 16 |
| causes transient | 16 |
| long time | 16 |
| mild respiratory | 16 |
| continuous variables | 16 |
| retrospective studies | 16 |
| proinflammatory cytokines | 16 |
| global alert | 16 |
| natural reservoirs | 16 |
| international license | 16 |
| antiviral drugs | 16 |
| significant difference | 16 |
| acid sequence | 16 |
| causative agent | 15 |
| two studies | 15 |
| reservoir host | 15 |
| world war | 15 |
| novel humanized | 15 |
| nasopharyngeal swab | 15 |
| southern part | 15 |
| cov spread | 15 |
| live mers | 15 |
| will help | 15 |
| genetic analysis | 15 |
| rapid response | 15 |
| fusion inhibitor | 15 |
| viral transmission | 15 |
| mild symptoms | 15 |
| severe lung | 15 |
| growth rate | 15 |
| positive control | 15 |
| referral hospital | 15 |
| epidemiological link | 15 |
| day mortality | 15 |
| candidate vaccine | 15 |
| copies ml | 15 |
| exceptionally potent | 15 |
| patient contact | 15 |
| sars cov | 15 |
| climate change | 15 |
| sialic acid | 15 |
| getah virus | 15 |
| ivanovsky institute | 15 |
| life cycle | 15 |
| korean society | 15 |
| nonstructural protein | 15 |
| controlled trial | 15 |
| innate antiviral | 15 |
| epidemiological characteristics | 15 |
| plaque assay | 15 |
| species restriction | 15 |
| cov may | 15 |
| polyclonal antibodies | 15 |
| study reported | 15 |
| nonfatal cases | 15 |
| cov population | 15 |
| transmission potential | 15 |
| spectrum antivirals | 15 |
| emerging novel | 15 |
| data analysis | 15 |
| old male | 15 |
| aspartate aminotransferase | 15 |
| infected cells | 15 |
| wild animals | 15 |
| near future | 15 |
| risk countries | 15 |
| isolation room | 15 |
| originally isolated | 15 |
| epidemiological analysis | 15 |
| including sars | 15 |
| phase ii | 15 |
| prospective descriptive | 15 |
| cov isolates | 15 |
| nasal turbinates | 15 |
| inflammatory cell | 15 |
| immunosorbent assay | 15 |
| community acquired | 15 |
| dna vaccines | 15 |
| novel betacoronavirus | 15 |
| final manuscript | 15 |
| infection caused | 15 |
| recombinant receptor | 15 |
| camel populations | 15 |
| analysis showed | 15 |
| infection middle | 15 |
| large numbers | 15 |
| epidemiological findings | 15 |
| protein microarray | 15 |
| coronavirus genome | 15 |
| foodborne illnesses | 15 |
| infection clinical | 15 |
| differential diagnosis | 15 |
| much lower | 15 |
| southern china | 15 |
| tohuman transmission | 15 |
| commons license | 15 |
| eastern siberia | 15 |
| small animal | 15 |
| czech republic | 15 |
| emerging coronavirus | 15 |
| granted medrxiv | 15 |
| analysis based | 15 |
| severely ill | 15 |
| author funder | 15 |
| foodborne illness | 15 |
| febrile illness | 15 |
| current knowledge | 15 |
| study also | 15 |
| bat sars | 15 |
| risk posed | 15 |
| epidemiological outbreak | 15 |
| serologic evidence | 15 |
| staphylococcus aureus | 15 |
| outbreak following | 15 |
| human cells | 15 |
| health department | 15 |
| pseudotyped mers | 15 |
| buffered saline | 15 |
| blood donors | 15 |
| adaptive evolution | 15 |
| rectal swabs | 15 |
| adenosine deaminase | 15 |
| pseudoparticle virus | 15 |
| interhuman transmissibility | 15 |
| specific human | 15 |
| several limitations | 15 |
| retrospective investigation | 15 |
| whether mers | 14 |
| chest radiographs | 14 |
| occupational exposure | 14 |
| secondary infections | 14 |
| day survival | 14 |
| viral challenge | 14 |
| east area | 14 |
| triple combination | 14 |
| renal syndrome | 14 |
| signifi cant | 14 |
| risk close | 14 |
| underlying diseases | 14 |
| emergency departments | 14 |
| com scientificreports | 14 |
| health security | 14 |
| case studies | 14 |
| cell infiltration | 14 |
| assays reveal | 14 |
| one case | 14 |
| viral species | 14 |
| sars epidemic | 14 |
| mosquitoes collected | 14 |
| small intestine | 14 |
| virus circulation | 14 |
| currently available | 14 |
| also detected | 14 |
| acute lung | 14 |
| organ damage | 14 |
| three days | 14 |
| animal care | 14 |
| cov receptor | 14 |
| new world | 14 |
| causes severe | 14 |
| antiviral regimen | 14 |
| major outbreak | 14 |
| cell membrane | 14 |
| coronavirus antibody | 14 |
| respiratory viral | 14 |
| using microneutralisation | 14 |
| one strain | 14 |
| global spread | 14 |
| genetic recombination | 14 |
| infectious mers | 14 |
| uriae ticks | 14 |
| alveolar epithelial | 14 |
| peptidase iv | 14 |
| early detection | 14 |
| emerging respiratory | 14 |
| test results | 14 |
| early diagnosis | 14 |
| key role | 14 |
| first time | 14 |
| cov neutralising | 14 |
| gene source | 14 |
| membrane protein | 14 |
| age groups | 14 |
| sectional study | 14 |
| sense rna | 14 |
| protein expression | 14 |
| disease associated | 14 |
| financial support | 14 |
| respiratory droplets | 14 |
| naturally infected | 14 |
| swine influenza | 14 |
| fatal outcome | 14 |
| multiple organ | 14 |
| results indicate | 14 |
| global public | 14 |
| airborne precautions | 14 |
| emerging infection | 14 |
| statistical analysis | 14 |
| passive immunotherapy | 14 |
| king abdulaziz | 14 |
| intermediate host | 14 |
| igg antibodies | 14 |
| insurance markets | 14 |
| like disease | 14 |
| three segments | 14 |
| different environmental | 14 |
| pneumonia patients | 14 |
| including mers | 14 |
| male sex | 14 |
| contaminated food | 14 |
| hospital admission | 14 |
| sri lanka | 14 |
| receptor cd | 14 |
| tissue tropism | 14 |
| russian federation | 14 |
| prototypical strain | 14 |
| transmissible gastroenteritis | 14 |
| endoplasmic reticulum | 14 |
| arabia clinical | 14 |
| transmission characteristics | 14 |
| per year | 14 |
| also showed | 14 |
| infected people | 14 |
| pilgrims returning | 14 |
| urgent need | 13 |
| lymph node | 13 |
| two decades | 13 |
| two years | 13 |
| comparator group | 13 |
| literature review | 13 |
| murine coronavirus | 13 |
| combination antiviral | 13 |
| interferon alpha | 13 |
| nasal secretions | 13 |
| human primate | 13 |
| infection isolation | 13 |
| severe clinical | 13 |
| economic growth | 13 |
| transmission chains | 13 |
| oc antigen | 13 |
| family bunyaviridae | 13 |
| ct value | 13 |
| globally reported | 13 |
| emerging middle | 13 |
| international spread | 13 |
| referral center | 13 |
| high degree | 13 |
| initial rrt | 13 |
| infect humans | 13 |
| syndrome coronaviruses | 13 |
| emerg infect | 13 |
| virus isolates | 13 |
| artibeus jamaicensis | 13 |
| top eight | 13 |
| antiviral compounds | 13 |
| hepatitis virus | 13 |
| first patient | 13 |
| viruses among | 13 |
| human populations | 13 |
| corticosteroid therapy | 13 |
| potential therapeutic | 13 |
| bovine serum | 13 |
| mild upper | 13 |
| calculated using | 13 |
| mucosal immunity | 13 |
| international health | 13 |
| different regions | 13 |
| kidney disease | 13 |
| camelus dromedaries | 13 |
| droplet precautions | 13 |
| two viruses | 13 |
| lesser extent | 13 |
| surveillance biases | 13 |
| air force | 13 |
| national institute | 13 |
| macaque model | 13 |
| marburg virus | 13 |
| host immune | 13 |
| orf ab | 13 |
| blood pressure | 13 |
| asymptomatic infections | 13 |
| like coronavirus | 13 |
| cytopathic effects | 13 |
| specific anti | 13 |
| laboratory confirmed | 13 |
| clinical outcome | 13 |
| acute pneumonia | 13 |
| disease progression | 13 |
| standard deviation | 13 |
| cov inoculation | 13 |
| least two | 13 |
| rna genome | 13 |
| arboviral zoonoses | 13 |
| burkina faso | 13 |
| enhanced ppe | 13 |
| among hcws | 13 |
| food production | 13 |
| cell response | 13 |
| camel exposures | 13 |
| european centre | 13 |
| type smallpox | 13 |
| viral pathogenesis | 13 |
| outbreak hospital | 13 |
| netherland dwarf | 13 |
| infection may | 13 |
| borne phleboviruses | 13 |
| case study | 13 |
| viral antigens | 13 |
| coronavirus nl | 13 |
| positive cases | 13 |
| transmission events | 13 |
| cov remains | 13 |
| highest risk | 13 |
| ninth report | 13 |
| iron age | 13 |
| among pilgrims | 13 |
| tissue samples | 13 |
| african bat | 13 |
| river delta | 13 |
| organ cultures | 13 |
| like coronaviruses | 13 |
| camelus dromedarius | 13 |
| accessory protein | 13 |
| serological analysis | 13 |
| many years | 13 |
| human lungs | 13 |
| treatment outcomes | 13 |
| data suggest | 13 |
| dwarf rabbits | 13 |
| tickborne encephalitis | 13 |
| sick men | 13 |
| war ii | 13 |
| hdpp expression | 13 |
| human cell | 13 |
| transcriptase polymerase | 13 |
| coronavirus rna | 13 |
| palm civets | 13 |
| potential mers | 13 |
| communicable diseases | 13 |
| first two | 13 |
| high proportion | 13 |
| viruses related | 13 |
| novel viruses | 13 |
| mg dl | 13 |
| viral particles | 13 |
| retrospective analysis | 13 |
| pcr results | 13 |
| previous study | 13 |
| hyalomma marginatum | 13 |
| graphpad prism | 13 |
| north africa | 13 |
| therapeutic efficacy | 13 |
| data show | 13 |
| east africa | 13 |
| cycle threshold | 13 |
| tylonycteris bat | 13 |
| mice treated | 13 |
| reading frames | 13 |
| fully understood | 13 |
| reported case | 13 |
| antigenic relationships | 13 |
| low level | 13 |
| powassan virus | 13 |
| prior probability | 13 |
| transmission occurred | 12 |
| genus nairovirus | 12 |
| rate among | 12 |
| breath samples | 12 |
| specific igg | 12 |
| animal experiments | 12 |
| doctor shopping | 12 |
| years later | 12 |
| imported middle | 12 |
| lung lesions | 12 |
| cov genomes | 12 |
| health regulations | 12 |
| betacoronavirus causing | 12 |
| considered statistically | 12 |
| common symptoms | 12 |
| general hospital | 12 |
| death among | 12 |
| high latitudes | 12 |
| feline coronavirus | 12 |
| female ratio | 12 |
| medrxiv preprint | 12 |
| days later | 12 |
| korea mers | 12 |
| clinical disease | 12 |
| chronic lung | 12 |
| human isolate | 12 |
| quality assessment | 12 |
| among imported | 12 |
| viral pathogens | 12 |
| vasopressor therapy | 12 |
| interpreted data | 12 |
| protein rbd | 12 |
| mild disease | 12 |
| underlying disease | 12 |
| short time | 12 |
| insurance products | 12 |
| north korea | 12 |
| epithelial cell | 12 |
| pediatric cases | 12 |
| respiratory illnesses | 12 |
| additional file | 12 |
| studies suggest | 12 |
| cov antigens | 12 |
| recent years | 12 |
| underlying comorbidities | 12 |
| clinical practice | 12 |
| human receptor | 12 |
| widespread infection | 12 |
| interim case | 12 |
| take place | 12 |
| serological studies | 12 |
| demographic characteristics | 12 |
| envelope glycoproteins | 12 |
| years ago | 12 |
| highly immunogenic | 12 |
| african mers | 12 |
| humanized neutralizing | 12 |
| california encephalitis | 12 |
| several days | 12 |
| common cold | 12 |
| geographical distribution | 12 |
| reduction neutralization | 12 |
| nasal cavity | 12 |
| medical research | 12 |
| demographic data | 12 |
| cov jordan | 12 |
| adaptive immune | 12 |
| human bronchial | 12 |
| syndrome clinical | 12 |
| exponential growth | 12 |
| host innate | 12 |
| biological properties | 12 |
| cov treatment | 12 |
| preliminary report | 12 |
| zealand rabbits | 12 |
| conspecific virus | 12 |
| possible cause | 12 |
| found among | 12 |
| year period | 12 |
| many cases | 12 |
| cov pcr | 12 |
| control precautions | 12 |
| beta interferon | 12 |
| induces severe | 12 |
| cov nucleocapsid | 12 |
| one hand | 12 |
| recent outbreak | 12 |
| clinical findings | 12 |
| serologic responses | 12 |
| human clinical | 12 |
| antibody levels | 12 |
| syndrome virus | 12 |
| i ifn | 12 |
| west africa | 12 |
| posterior probability | 12 |
| dry cough | 12 |
| remains unknown | 12 |
| regression analysis | 12 |
| since immigration | 12 |
| virus vaccine | 12 |
| serum sample | 12 |
| laboratory results | 12 |
| negative results | 12 |
| similar results | 12 |
| state collection | 12 |
| new arbovirus | 12 |
| protein gene | 12 |
| humoral immune | 12 |
| coronavirus fusion | 12 |
| cd monoclonal | 12 |
| may occur | 12 |
| cov detection | 12 |
| civil society | 12 |
| hdpp tg | 12 |
| fi nal | 12 |
| disease outbreaks | 12 |
| blood cell | 12 |
| severe covid | 12 |
| taken together | 12 |
| deep sequencing | 12 |
| updated information | 12 |
| among mers | 12 |
| flow cytometry | 12 |
| wide range | 12 |
| healthcare professionals | 12 |
| positive test | 12 |
| epidemiological studies | 12 |
| raw milk | 12 |
| using real | 12 |
| secondary infection | 12 |
| emergency committee | 12 |
| cleavage site | 12 |
| likely source | 12 |
| patients presenting | 12 |
| fecal samples | 12 |
| zone iv | 12 |
| operating rooms | 12 |
| influenza infection | 12 |
| acid sequences | 12 |
| emerging diseases | 12 |
| target cell | 12 |
| bat cov | 12 |
| acquired cases | 12 |
| oxygen saturation | 12 |
| underlying conditions | 12 |
| higher levels | 12 |
| insurance industry | 12 |
| study found | 12 |
| two human | 12 |
| western countries | 12 |
| coronavirus date | 12 |
| imported mers | 12 |
| khabarovsk krai | 12 |
| categorical variables | 12 |
| pregnant woman | 12 |
| large tertiary | 12 |
| korean mers | 12 |
| apache ii | 12 |
| fetal bovine | 11 |
| current study | 11 |
| also observed | 11 |
| statistical significance | 11 |
| data available | 11 |
| kul virus | 11 |
| arab middle | 11 |
| become infected | 11 |
| protective effect | 11 |
| cov diagnosis | 11 |
| viral pneumonia | 11 |
| i clinical | 11 |
| commander islands | 11 |
| east asians | 11 |
| including certain | 11 |
| single hospital | 11 |
| southern taiga | 11 |
| seasonal influenza | 11 |
| binding site | 11 |
| western part | 11 |
| time points | 11 |
| may lead | 11 |
| core domain | 11 |
| chest ct | 11 |
| coronavirus human | 11 |
| dromedary wnv | 11 |
| national health | 11 |
| glycoproteins gn | 11 |
| international severe | 11 |
| multiple generations | 11 |
| sputum samples | 11 |
| global summary | 11 |
| time point | 11 |
| cov testing | 11 |
| outbreak members | 11 |
| eight emerging | 11 |
| side effects | 11 |
| food outlets | 11 |
| sick man | 11 |
| days vs | 11 |
| social distancing | 11 |
| current status | 11 |
| volga river | 11 |
| tract tissues | 11 |
| tissue distribution | 11 |
| causing sars | 11 |
| coronavirus vaccines | 11 |
| generation time | 11 |
| recombinant modified | 11 |
| donor rabbits | 11 |
| authors read | 11 |
| ace receptor | 11 |
| signifi cantly | 11 |
| findings may | 11 |
| varying degrees | 11 |
| elevated ast | 11 |
| east region | 11 |
| without tpa | 11 |
| vaccine induces | 11 |
| blood samples | 11 |
| camels antibodies | 11 |
| health careeassociated | 11 |
| financial services | 11 |
| mice expressing | 11 |
| associated infections | 11 |
| supportive treatment | 11 |
| antibody titres | 11 |
| icu patients | 11 |
| protease inhibitor | 11 |
| randomized clinical | 11 |
| host response | 11 |
| arabia evidence | 11 |
| safe food | 11 |
| another zoonotic | 11 |
| ricinus ticks | 11 |
| molecular characterization | 11 |
| illness associated | 11 |
| congo haemorrhagic | 11 |
| largest outbreak | 11 |
| independent risk | 11 |
| limited data | 11 |
| studies using | 11 |
| final outcome | 11 |
| epidemiologic data | 11 |
| intermediate hosts | 11 |
| virus clearance | 11 |
| developed pneumonia | 11 |
| saharan africa | 11 |
| associated cases | 11 |
| molecule inhibitors | 11 |
| cov activities | 11 |
| survival rate | 11 |
| others viruses | 11 |
| table shows | 11 |
| neutralizing activity | 11 |
| etiologically linked | 11 |
| epidemiological assessment | 11 |
| three viruses | 11 |
| south america | 11 |
| cell types | 11 |
| major role | 11 |
| main operating | 11 |
| health systems | 11 |
| relative risk | 11 |
| technical meeting | 11 |
| sustained human | 11 |
| case control | 11 |
| european union | 11 |
| camel interactions | 11 |
| ixodes uriae | 11 |
| fraction yield | 11 |
| infected dromedaries | 11 |
| zoonotic betacoronavirus | 11 |
| international collaboration | 11 |
| crucial role | 11 |
| vaccines based | 11 |
| human vaccine | 11 |
| recombination events | 11 |
| cov entry | 11 |
| reduced viral | 11 |
| serum specimens | 11 |
| viral etiology | 11 |
| contact precautions | 11 |
| final version | 11 |
| also described | 11 |
| transcription pcr | 11 |
| common ancestor | 11 |
| camels may | 11 |
| animal reservoirs | 11 |
| potent inhibitors | 11 |
| pulmonary disease | 11 |
| viral excretion | 11 |
| factors related | 11 |
| landscape belts | 11 |
| case clusters | 11 |
| active surveillance | 11 |
| airway epithelium | 11 |
| well plates | 11 |
| initial outbreak | 11 |
| arbovirus isolated | 11 |
| first week | 11 |
| significantly associated | 11 |
| syrian hamsters | 11 |
| receptor dpp | 11 |
| inhibitors targeting | 11 |
| strongly inhibited | 11 |
| symptomatic mers | 11 |
| four patients | 11 |
| arboviruses including | 11 |
| coronavirus nucleocapsid | 11 |
| replication induces | 11 |
| vaccine approaches | 11 |
| cov middle | 11 |
| growth rates | 11 |
| vitro cytopathology | 11 |
| viral transport | 11 |
| related cases | 11 |
| dry ice | 11 |
| genome fraction | 11 |
| patients requiring | 11 |
| korea clinical | 11 |
| hajj pilgrimage | 11 |
| study hospital | 11 |
| nile fever | 11 |
| log reduction | 11 |
| new drug | 11 |
| air sample | 11 |
| including diabetes | 11 |
| secondary mers | 11 |
| virus spread | 11 |
| peripheral blood | 11 |
| cov patient | 11 |
| clinical picture | 11 |
| transmission risk | 11 |
| based subunit | 11 |
| genetic variation | 11 |
| disease pathogenesis | 11 |
| hae cultures | 11 |
| retrieved articles | 11 |
| dependent rna | 11 |
| cov positive | 11 |
| highest number | 11 |
| cov investigation | 11 |
| cytopathic effect | 11 |
| south east | 11 |
| russian state | 11 |
| related coronavirus | 11 |
| different mers | 11 |
| significant increase | 11 |
| crispr cas | 11 |
| two independent | 11 |
| high genetic | 10 |
| arabia reported | 10 |
| isolates revealed | 10 |
| blood products | 10 |
| overcrowded emergency | 10 |
| antibody specifically | 10 |
| immunohistochemical staining | 10 |
| emerging disease | 10 |
| nucleic acids | 10 |
| rna copies | 10 |
| virus rna | 10 |
| human health | 10 |
| israel epi | 10 |
| lower lung | 10 |
| lassa fever | 10 |
| global threat | 10 |
| published studies | 10 |
| infection tracked | 10 |
| developed mers | 10 |
| isl unitedarabemirates | 10 |
| kidney cells | 10 |
| fusion inhibitors | 10 |
| phylogenetic trees | 10 |
| neutralisation assay | 10 |
| knowledge gaps | 10 |
| state security | 10 |
| cov pandemic | 10 |
| antibody protects | 10 |
| cases occurred | 10 |
| control recommendations | 10 |
| care setting | 10 |
| study ribavirin | 10 |
| endotracheal intubation | 10 |
| recently emerged | 10 |
| argasidae ticks | 10 |
| int csr | 10 |
| isl israel | 10 |
| nosocomial mers | 10 |
| airborne infection | 10 |
| associated deaths | 10 |
| medical sciences | 10 |
| phase iii | 10 |
| multifacility outbreak | 10 |
| product development | 10 |
| specific antibody | 10 |
| findings suggest | 10 |
| multicenter retrospective | 10 |
| brain tissue | 10 |
| higher mortality | 10 |
| human polyclonal | 10 |
| cov circulation | 10 |
| private hospital | 10 |
| subclinical infection | 10 |
| signaling pathways | 10 |
| russian far | 10 |
| sat members | 10 |
| people infected | 10 |
| ppe use | 10 |
| expressing hdpp | 10 |
| analysis using | 10 |
| pcr positive | 10 |
| humans middle | 10 |
| environmental samples | 10 |
| developed fever | 10 |
| health implications | 10 |
| disease emergence | 10 |
| jeddah outbreak | 10 |
| alveolar cavities | 10 |
| early identification | 10 |
| insurance sector | 10 |
| potential source | 10 |
| patients representing | 10 |
| health concern | 10 |
| isl turkey | 10 |
| acute febrile | 10 |
| turkey epi | 10 |
| research groups | 10 |
| cov seroprevalence | 10 |
| environmental cleaning | 10 |
| adapted mers | 10 |
| animal market | 10 |
| novel group | 10 |
| human igg | 10 |
| include homologues | 10 |
| patients suspected | 10 |
| chest radiography | 10 |
| including fever | 10 |
| study provides | 10 |
| immunofluorescence assay | 10 |
| severe influenza | 10 |
| prone positioning | 10 |
| superspreading events | 10 |
| sequence alignment | 10 |
| therapeutic option | 10 |
| major challenge | 10 |
| coronavirus nsp | 10 |
| coronavirus referral | 10 |
| isl saudiarabia | 10 |
| virus particles | 10 |
| foodborne diseases | 10 |
| transport medium | 10 |
| google scholar | 10 |
| novel corona | 10 |
| potent neutralizing | 10 |
| human cd | 10 |
| icu stay | 10 |
| armed forces | 10 |
| viral vectors | 10 |
| generation cases | 10 |
| virus titration | 10 |
| mild cases | 10 |
| kalmyk republic | 10 |
| throat swab | 10 |
| negative controls | 10 |
| potent human | 10 |
| ang ii | 10 |
| confirmed patients | 10 |
| data indicate | 10 |
| travelers returning | 10 |
| three strains | 10 |
| electronic medical | 10 |
| preventive treatment | 10 |
| south china | 10 |
| health england | 10 |
| putus pick | 10 |
| transmission occurs | 10 |
| reproductive number | 10 |
| chinese horseshoe | 10 |
| agriculture organization | 10 |
| diseases caused | 10 |
| recombinant adenovirus | 10 |
| infection case | 10 |
| positive samples | 10 |
| unitedarabemirates epi | 10 |
| erasmus medical | 10 |
| korea centers | 10 |
| risk groups | 10 |
| sea basin | 10 |
| high rates | 10 |
| coronavirus quasispecies | 10 |
| comprehensive review | 10 |
| nasal carriage | 10 |
| toscana virus | 10 |
| local health | 10 |
| delivering middle | 10 |
| infectious respiratory | 10 |
| large case | 10 |
| wild carnivores | 10 |
| research center | 10 |
| infections hospital | 10 |
| nasal epithelium | 10 |
| serologic assays | 10 |
| i pneumocytes | 10 |
| vitro anti | 10 |
| camel workers | 10 |
| eastern asia | 10 |
| clinical decision | 10 |
| analysis revealed | 10 |
| therapeutic interventions | 10 |
| aedes albopictus | 10 |
| oral ribavirin | 10 |
| related virus | 10 |
| avian coronavirus | 10 |
| based assays | 10 |
| every year | 10 |
| us centers | 10 |
| emerging viral | 10 |
| virus neutralization | 10 |
| food control | 10 |
| immunocompromised patients | 10 |
| crimean hemorrhagic | 10 |
| widely used | 10 |
| acid residues | 10 |
| fi ndings | 10 |
| took place | 10 |
| outbreak investigations | 10 |
| virus group | 10 |
| might also | 10 |
| yellow fever | 10 |
| aedes mosquitoes | 10 |
| rhesus monkeys | 10 |
| cov research | 10 |
| infection rates | 10 |
| ct findings | 10 |
| viral proteases | 10 |
| west coast | 10 |
| disease course | 10 |
| may help | 10 |
| syndrome generation | 10 |
| virus titers | 10 |
| economic development | 10 |
| common respiratory | 10 |
| pcr diagnosis | 10 |
| viral envelope | 10 |
| bibliometric analysis | 10 |
| arboviral infections | 10 |
| laboratory diagnosis | 10 |
| known mers | 10 |
| water supplies | 10 |
| transmission may | 10 |
| nhp models | 10 |
| scientific research | 10 |
| white blood | 10 |
| pathogenic influenza | 10 |
| coronavirus papain | 10 |
| future studies | 10 |
| zoonotic potential | 10 |
| mers transmission | 10 |
| organ dysfunction | 10 |
| northern part | 10 |
| cov hku | 10 |
| also associated | 10 |
| specifically targeting | 10 |
| poor countries | 10 |
| mass gathering | 10 |
| two hospitals | 10 |
| expressing mers | 10 |
| group viruses | 10 |
| virus cultured | 10 |
| global technical | 10 |
| rna synthesis | 10 |
| bat covs | 10 |
| three different | 10 |
| many studies | 10 |
| epidemic outbreaks | 10 |
| super spreaders | 10 |
| days postinoculation | 10 |
| exact test | 10 |
| assay specificity | 10 |
| natural hosts | 10 |
| infection consortium | 10 |
| pooled estimate | 10 |
| neutralization assay | 10 |
| saudiarabia epi | 10 |
| time course | 10 |
| coronavirus pandemic | 10 |
| least days | 10 |
| university hospital | 10 |
| zika virus | 10 |
| antigenically related | 9 |
| case patient | 9 |
| immunological responses | 9 |
| inhibitory concentration | 9 |
| transchromosomic bovines | 9 |
| new emerging | 9 |
| natural disasters | 9 |
| high rate | 9 |
| invasive ventilation | 9 |
| patient care | 9 |
| mers vaccine | 9 |
| study protocol | 9 |
| adenovirus vector | 9 |
| cov reported | 9 |
| mice transgenic | 9 |
| antiviral peptides | 9 |
| anas platyrhynchos | 9 |
| intellectual content | 9 |
| fold serial | 9 |
| bacillus cereus | 9 |
| lethal outcomes | 9 |
| young children | 9 |
| detectable antibodies | 9 |
| reaction assays | 9 |
| basic reproduction | 9 |
| will likely | 9 |
| lethal respiratory | 9 |
| chronic kidney | 9 |
| mva based | 9 |
| severe human | 9 |
| less likely | 9 |
| cov accessory | 9 |
| day postinfection | 9 |
| national institutes | 9 |
| different genotypes | 9 |
| sectional surveillance | 9 |
| ml mers | 9 |
| information age | 9 |
| local customs | 9 |
| dead survived | 9 |
| human ace | 9 |
| subgenus embecovirus | 9 |
| gambian fruit | 9 |
| wbc count | 9 |
| natural antagonist | 9 |
| ixodidae tick | 9 |
| first step | 9 |
| information regarding | 9 |
| different species | 9 |
| significantly increased | 9 |
| travellers returning | 9 |
| pfu ml | 9 |
| ixodes ricinus | 9 |
| elevated serum | 9 |
| highly potent | 9 |
| transmission route | 9 |
| influenza vaccination | 9 |
| determine whether | 9 |
| research activity | 9 |
| associated factors | 9 |
| confi rmation | 9 |
| strain isolated | 9 |
| serologic studies | 9 |
| ct scan | 9 |
| lethal mers | 9 |
| developing severe | 9 |
| new strain | 9 |
| hypoxemic respiratory | 9 |
| infect doi | 9 |
| serum creatinine | 9 |
| medical history | 9 |
| cellular receptor | 9 |
| three novel | 9 |
| unpasteurized camel | 9 |
| copy number | 9 |
| clinical samples | 9 |
| faecal samples | 9 |
| african green | 9 |
| animal origin | 9 |
| zoonotic viruses | 9 |
| oedematous alveolar | 9 |
| heart failure | 9 |
| disease transmission | 9 |
| adjusted odds | 9 |
| clinical research | 9 |
| care associated | 9 |
| arbovirus infections | 9 |
| preliminary epidemiological | 9 |
| porcine epidemic | 9 |
| genetic material | 9 |
| transmission heterogeneity | 9 |
| human primary | 9 |
| twentieth century | 9 |
| causes widespread | 9 |
| important intellectual | 9 |
| possibly linked | 9 |
| may cause | 9 |
| mers infections | 9 |
| pathogenic coronaviruses | 9 |
| communicable disease | 9 |
| serine protease | 9 |
| time frame | 9 |
| days since | 9 |
| will provide | 9 |
| pressure rooms | 9 |
| eye protection | 9 |
| large proportion | 9 |
| twice daily | 9 |
| mammalian cells | 9 |
| critical revision | 9 |
| medical record | 9 |
| recombinant protein | 9 |
| different types | 9 |
| antigenic group | 9 |
| hospital staff | 9 |
| highly sensitive | 9 |
| prognostic factors | 9 |
| cov surveillance | 9 |
| commercially available | 9 |
| health threat | 9 |
| livestock dromedaries | 9 |
| cell fusion | 9 |
| one hundred | 9 |
| arab region | 9 |
| computed tomography | 9 |
| previously published | 9 |
| west african | 9 |
| antiviral treatments | 9 |
| species barrier | 9 |
| patients without | 9 |
| clinically developed | 9 |
| many different | 9 |
| dhori virus | 9 |
| mediated entry | 9 |
| additional cases | 9 |
| eastern part | 9 |
| known human | 9 |
| coronavirus treatment | 9 |
| gcc countries | 9 |
| arabia epidemiological | 9 |
| alveolar septum | 9 |
| coronavirus clinical | 9 |
| coronavirus cases | 9 |
| detect mers | 9 |
| bibliometric studies | 9 |
| immune serum | 9 |
| camel barn | 9 |
| human mab | 9 |
| community transmission | 9 |
| assay panel | 9 |
| rna detection | 9 |
| abdulaziz medical | 9 |
| mers pneumonia | 9 |
| molecular clock | 9 |
| candidate vaccines | 9 |
| human interface | 9 |
| dairy products | 9 |
| raw camel | 9 |
| nucleotide sequences | 9 |
| virus vaccines | 9 |
| human lung | 9 |
| diagnostic test | 9 |
| high morbidity | 9 |
| natural history | 9 |
| exposure device | 9 |
| pp ab | 9 |
| within hours | 9 |
| human pathology | 9 |
| household transmission | 9 |
| virus challenge | 9 |
| sialic acids | 9 |
| controlled clinical | 9 |
| clinical validation | 9 |
| common murre | 9 |
| rtpcr positive | 9 |
| former ussr | 9 |
| cov qatar | 9 |
| recent travel | 9 |
| nucleoside analogue | 9 |
| molecular evolution | 9 |
| ground glass | 9 |
| korea transmission | 9 |
| two main | 9 |
| fulica atra | 9 |
| second week | 9 |
| blood transfusion | 9 |
| emerging infections | 9 |
| respiratory epithelium | 9 |
| submucosal glands | 9 |
| may provide | 9 |
| observed among | 9 |
| rbd residues | 9 |
| using data | 9 |
| recent outbreaks | 9 |
| hospital settings | 9 |
| barn owned | 9 |
| drug compounds | 9 |
| reported among | 9 |
| may require | 9 |
| developed drugs | 9 |
| city health | 9 |
| migrating birds | 9 |
| reactors among | 9 |
| biological specimens | 9 |
| milk collected | 9 |
| myodes glareolus | 9 |
| antibody reactors | 9 |
| contact investigations | 9 |
| critical role | 9 |
| coronavirus patients | 9 |
| ill mers | 9 |
| adult camels | 9 |
| cases per | 9 |
| surveillance system | 9 |
| selective sweep | 9 |
| sample originating | 9 |
| time interval | 9 |
| associated infection | 9 |
| argas ticks | 9 |
| possible genetic | 9 |
| conducted using | 9 |
| coronaviruses reveals | 9 |
| laikipia county | 9 |
| proteolytic processing | 9 |
| kinetic analysis | 9 |
| passive transfer | 9 |
| searched pubmed | 9 |
| case definitions | 9 |
| like symptoms | 9 |
| detected among | 9 |
| farm animals | 9 |
| lung samples | 9 |
| antibody tests | 9 |
| interspecies transmission | 9 |
| virus closely | 9 |
| virus evolution | 9 |
| human case | 9 |
| supportive therapy | 9 |
| cyclophilin inhibitors | 9 |
| reservoir hosts | 9 |
| specific mers | 9 |
| inflammatory response | 9 |
| cov referral | 9 |
| fusion core | 9 |
| fusion peptide | 9 |
| large quantities | 9 |
| recent middle | 9 |
| laboratory data | 9 |
| applied biosystems | 9 |
| global level | 9 |
| insurance company | 9 |
| approved drugs | 9 |
| systematic reviews | 9 |
| whole blood | 9 |
| library identifies | 9 |
| safety issues | 9 |
| maximum likelihood | 9 |
| informed consent | 9 |
| probable transmission | 9 |
| fatal human | 9 |
| vaccine based | 9 |
| independent states | 9 |
| care units | 9 |
| mers virus | 9 |
| vaccine design | 9 |
| infected alpacas | 9 |
| corticosteroid treatment | 9 |
| indirect immunofluorescence | 9 |
| second case | 9 |
| humans possibly | 9 |
| serotine bat | 9 |
| pressure operating | 9 |
| structural protein | 9 |
| three groups | 9 |
| close relatives | 9 |
| care response | 9 |
| experimental transmission | 9 |
| interferon antagonists | 9 |
| highly conserved | 8 |
| infected travellers | 8 |
| environmental factors | 8 |
| compound library | 8 |
| novel mammalian | 8 |
| affected areas | 8 |
| single imported | 8 |
| ribavirin interferon | 8 |
| using graphpad | 8 |
| amotosalen uva | 8 |
| marmoset model | 8 |
| term excretion | 8 |
| virus among | 8 |
| member states | 8 |
| respiratory specimen | 8 |
| using mers | 8 |
| neutralization tests | 8 |
| novel recombinant | 8 |
| two weeks | 8 |
| healthcare providers | 8 |
| strict implementation | 8 |
| laboratory animals | 8 |
| animal populations | 8 |
| initial infection | 8 |
| articles published | 8 |
| field studies | 8 |
| often used | 8 |
| ifn response | 8 |
| infection treated | 8 |
| infected pneumonia | 8 |
| cohort studies | 8 |
| population growth | 8 |
| reported laboratory | 8 |
| healthcare associated | 8 |
| alveolar epithelium | 8 |
| may increase | 8 |
| one example | 8 |
| vertebrate host | 8 |
| outbreak member | 8 |
| especially among | 8 |
| cov therapies | 8 |
| aedes aegypti | 8 |
| initial presentation | 8 |
| respir viruses | 8 |
| coronavirus isolates | 8 |
| severe infection | 8 |
| study revealed | 8 |
| secondary attack | 8 |
| potential epidemiological | 8 |
| exposure history | 8 |
| creatinine clearance | 8 |
| causing severe | 8 |
| hospital contacts | 8 |
| viral genomic | 8 |
| red cross | 8 |
| wnv strains | 8 |
| organizing pneumonia | 8 |
| escape mutants | 8 |
| alanine aminotransferase | 8 |
| probable risk | 8 |
| one day | 8 |
| cell activation | 8 |
| mini kit | 8 |
| human adenovirus | 8 |
| low prevalence | 8 |
| hospital room | 8 |
| chinese medicine | 8 |
| community case | 8 |
| traditional chinese | 8 |
| cov medical | 8 |
| without respiratory | 8 |
| nitric oxide | 8 |
| antibiotic resistance | 8 |
| cov pl | 8 |
| first immunization | 8 |
| detected mers | 8 |
| pressure room | 8 |
| host range | 8 |
| approved compound | 8 |
| patients clinical | 8 |
| typhoid fever | 8 |
| cellular immunogenicity | 8 |
| encephalitis viruses | 8 |
| susan i | 8 |
| years since | 8 |
| serological methods | 8 |
| three patients | 8 |
| receptor usage | 8 |
| poor prognosis | 8 |
| jordan middle | 8 |
| dromedary calf | 8 |
| cov isolate | 8 |
| airborne routes | 8 |
| goat anti | 8 |
| cases middle | 8 |
| several times | 8 |
| acid substitutions | 8 |
| noninvasive ventilation | 8 |
| cov global | 8 |
| one third | 8 |
| influenza pandemic | 8 |
| emerging viruses | 8 |
| gastroenteritis virus | 8 |
| segment encodes | 8 |
| lung homogenates | 8 |
| study using | 8 |
| pediatric age | 8 |
| small molecule | 8 |
| aged years | 8 |
| overall mortality | 8 |
| german hospital | 8 |
| vector borne | 8 |
| neutralizing human | 8 |
| vivo studies | 8 |
| binding domains | 8 |
| outbreak occurred | 8 |
| viral infectivity | 8 |
| unlike sars | 8 |
| arab countries | 8 |
| described elsewhere | 8 |
| syndrome severe | 8 |
| vitro stimulation | 8 |
| host infectivity | 8 |
| clinical use | 8 |
| severe outcome | 8 |
| replication cycle | 8 |
| madinah city | 8 |
| tyuleniy island | 8 |
| among people | 8 |
| known cases | 8 |
| received ribavirin | 8 |
| epidemiological status | 8 |
| renal function | 8 |
| central asian | 8 |
| inoculated rabbits | 8 |
| wash fluid | 8 |
| per day | 8 |
| cov plpro | 8 |
| masked palm | 8 |
| cell tropism | 8 |
| saudi moh | 8 |
| borne flaviviruses | 8 |
| shedding dromedaries | 8 |
| several groups | 8 |
| natural host | 8 |
| two hospital | 8 |
| community outbreak | 8 |
| van den | 8 |
| clinical recovery | 8 |
| associated mers | 8 |
| signal peptide | 8 |
| double staining | 8 |
| diagnosis delay | 8 |
| sars virus | 8 |
| two doses | 8 |
| reported direct | 8 |
| insurance demand | 8 |
| adverse effects | 8 |
| security council | 8 |
| den brand | 8 |
| survival data | 8 |
| nosocomial clusters | 8 |
| vice versa | 8 |
| rational design | 8 |
| camel vaccine | 8 |
| japanese pipistrelle | 8 |
| based discovery | 8 |
| positive result | 8 |
| following mers | 8 |
| med doi | 8 |
| gold standard | 8 |
| anthropogenic biocenoses | 8 |
| health insurance | 8 |
| cov disease | 8 |
| clinical diagnosis | 8 |
| market development | 8 |
| appropriate infection | 8 |
| potential role | 8 |
| new human | 8 |
| financial crisis | 8 |
| additional data | 8 |
| thermo fisher | 8 |
| per patient | 8 |
| otitis media | 8 |
| foreign companies | 8 |
| human sera | 8 |
| main vector | 8 |
| day incubation | 8 |
| clinical forms | 8 |
| identified mers | 8 |
| among wild | 8 |
| like cov | 8 |
| therapeutic countermeasures | 8 |
| immunocompromised hosts | 8 |
| betacoronavirus emc | 8 |
| receptor specificity | 8 |
| delayed induction | 8 |
| subgenomic rnas | 8 |
| antimicrobial drugs | 8 |
| disseminated intravascular | 8 |
| genus alphacoronavirus | 8 |
| several countries | 8 |
| infection kinetics | 8 |
| quantitative pcr | 8 |
| radiological findings | 8 |
| lung function | 8 |
| respiratory tracts | 8 |
| infection mers | 8 |
| intratracheal inoculation | 8 |
| reported days | 8 |
| gulf countries | 8 |
| fatality ratio | 8 |
| ixodid ticks | 8 |
| deep tracheal | 8 |
| odds ratios | 8 |
| exclusion criteria | 8 |
| drug administration | 8 |
| military medical | 8 |
| female camels | 8 |
| ankara delivering | 8 |
| last years | 8 |
| level risk | 8 |
| tract disease | 8 |
| poorly understood | 8 |
| first isolation | 8 |
| specific treatment | 8 |
| igg antibody | 8 |
| asymptomatic middle | 8 |
| probable case | 8 |
| aerosol generating | 8 |
| targeting receptor | 8 |
| fatal respiratory | 8 |
| longitudinal study | 8 |
| control implications | 8 |
| requiring mechanical | 8 |
| prevention control | 8 |
| young camels | 8 |
| online version | 8 |
| inhibit sars | 8 |
| developed acute | 8 |
| year old | 8 |
| much stronger | 8 |
| acute phase | 8 |
| animal nose | 8 |
| recombinant virus | 8 |
| drug discovery | 8 |
| viruses belonging | 8 |
| countries including | 8 |
| well documented | 8 |
| cov therapy | 8 |
| rapid immunochromatographic | 8 |
| novel virus | 8 |
| collected according | 8 |
| interim infection | 8 |
| genotype i | 8 |
| update middle | 8 |
| batai virus | 8 |
| pulmonary pathology | 8 |
| epidemiologic characteristics | 8 |
| clinical development | 8 |
| strong neutralizing | 8 |
| nauki i | 8 |
| univariate analysis | 8 |
| saudi intensive | 8 |
| higher among | 8 |
| virus outbreak | 8 |
| sample collection | 8 |
| culex pipiens | 8 |
| may result | 8 |
| face masks | 8 |
| baloxavir marboxil | 8 |
| camels tested | 8 |